An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 24 Apr 2018 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 24 Apr 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2019.
- 24 Apr 2018 Status changed from recruiting to active, no longer recruiting.